Journal
LUNG CANCER
Volume 50, Issue 1, Pages 83-86Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2005.04.010
Keywords
malignant mesothelioma; treatment; imatinib; PDGF; c-kit; anti-cancer agents
Categories
Ask authors/readers for more resources
Twenty-five patients with histologically proven malignant mesotheliorna participated in a trial of imatinib mesylate (Glivec) with a starting dose of 400mg per day taken orally, up to a maximal. dose of 800 mg. No responses were observed in the patient group, while three patients showed prolonged (> 6 months) stabilization of disease. The median survival time was 398 days (range 88-840); the median time to progression was 63 days (range 29-275). Side effects of the medication were mild and included edema, nausea, constipation and diarrhea. We conclude that further investigation with monotherapy imatinib in mesothetioma is not warranted. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available